180 related articles for article (PubMed ID: 34206484)
1. The Anticancer Effects of FDI-6, a FOXM1 Inhibitor, on Triple Negative Breast Cancer.
Ulhaka K; Kanokwiroon K; Khongkow M; Bissanum R; Khunpitak T; Khongkow P
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206484
[TBL] [Abstract][Full Text] [Related]
2. FOXM1 Inhibitors as Potential Diagnostic Agents: First Generation of a PET Probe Targeting FOXM1 To Detect Triple-Negative Breast Cancer in vitro and in vivo.
Pérez DJ; Amirhossein Tabatabaei Dakhili S; Bergman C; Dufour J; Wuest M; Juengling FD; Wuest F; Velázquez-Martínez CA
ChemMedChem; 2021 Dec; 16(24):3720-3729. PubMed ID: 34402202
[TBL] [Abstract][Full Text] [Related]
3. [Forkhead domain inhibitor-6 (FDI-6) increases apoptosis and inhibits invasion and migration of laryngeal carcinoma cells by down-regulating nuclear FoxM1].
Liu Y; Zhu L; Wen T; Wan J; Lei Y; Chen H
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 May; 33(5):611-616. PubMed ID: 28502298
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
5. Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer.
Arora R; Yates C; Gary BD; McClellan S; Tan M; Xi Y; Reed E; Piazza GA; Owen LB; Dean-Colomb W
PLoS One; 2014; 9(6):e98370. PubMed ID: 24896091
[TBL] [Abstract][Full Text] [Related]
6. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
Gao Z; Shi M; Wang Y; Chen J; Ou Y
Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
[TBL] [Abstract][Full Text] [Related]
7. FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair.
Wang SP; Wu SQ; Huang SH; Tang YX; Meng LQ; Liu F; Zhu QH; Xu YG
Cell Death Dis; 2021 Dec; 12(12):1138. PubMed ID: 34880209
[TBL] [Abstract][Full Text] [Related]
8. FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer.
Hamurcu Z; Kahraman N; Ashour A; Ozpolat B
Breast Cancer Res Treat; 2017 Jun; 163(3):485-493. PubMed ID: 28361350
[TBL] [Abstract][Full Text] [Related]
9. Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1.
Cınar V; Hamurcu Z; Guler A; Nurdinov N; Ozpolat B
Breast Cancer; 2022 Nov; 29(6):1106-1120. PubMed ID: 36006564
[TBL] [Abstract][Full Text] [Related]
10. Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.
Bayraktar R; Ivan C; Bayraktar E; Kanlikilicer P; Kabil NN; Kahraman N; Mokhlis HA; Karakas D; Rodriguez-Aguayo C; Arslan A; Sheng J; Wong S; Lopez-Berestein G; Calin GA; Ozpolat B
Clin Cancer Res; 2018 Sep; 24(17):4225-4241. PubMed ID: 29748184
[No Abstract] [Full Text] [Related]
11. FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways.
Wu SQ; Huang SH; Lin QW; Tang YX; Huang L; Xu YG; Wang SP
Pharmacol Res; 2022 Jan; 175():106040. PubMed ID: 34954029
[TBL] [Abstract][Full Text] [Related]
12. KR-33028, a potent inhibitor of the Na
Amith SR; Wilkinson JM; Fliegel L
Biochem Pharmacol; 2016 Oct; 118():31-39. PubMed ID: 27521504
[TBL] [Abstract][Full Text] [Related]
13. Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs.
Guillen VS; Ziegler Y; Gopinath C; Kumar S; Dey P; Plotner BN; Dawson NZ; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS
Breast Cancer Res Treat; 2023 Apr; 198(3):607-621. PubMed ID: 36847915
[TBL] [Abstract][Full Text] [Related]
14. FOXM1 plays a role in autophagy by transcriptionally regulating Beclin-1 and LC3 genes in human triple-negative breast cancer cells.
Hamurcu Z; Delibaşı N; Nalbantoglu U; Sener EF; Nurdinov N; Tascı B; Taheri S; Özkul Y; Donmez-Altuntas H; Canatan H; Ozpolat B
J Mol Med (Berl); 2019 Apr; 97(4):491-508. PubMed ID: 30729279
[TBL] [Abstract][Full Text] [Related]
15. SP1-independent inhibition of FOXM1 by modified thiazolidinediones.
Tabatabaei Dakhili SA; Pérez DJ; Gopal K; Haque M; Ussher JR; Kashfi K; Velázquez-Martínez CA
Eur J Med Chem; 2021 Jan; 209():112902. PubMed ID: 33069434
[TBL] [Abstract][Full Text] [Related]
16. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
17. Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple-negative breast cancer.
Yang N; Wang C; Wang J; Wang Z; Huang D; Yan M; Kamran M; Liu Q; Xu B
J Cell Mol Med; 2019 Sep; 23(9):6442-6453. PubMed ID: 31359594
[TBL] [Abstract][Full Text] [Related]
18. HMGA1 promotes breast cancer angiogenesis supporting the stability, nuclear localization and transcriptional activity of FOXM1.
Zanin R; Pegoraro S; Ros G; Ciani Y; Piazza S; Bossi F; Bulla R; Zennaro C; Tonon F; Lazarevic D; Stupka E; Sgarra R; Manfioletti G
J Exp Clin Cancer Res; 2019 Jul; 38(1):313. PubMed ID: 31311575
[TBL] [Abstract][Full Text] [Related]
19. Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer.
Katzenellenbogen BS; Guillen VS; Katzenellenbogen JA
Breast Cancer Res; 2023 Jun; 25(1):76. PubMed ID: 37370117
[TBL] [Abstract][Full Text] [Related]
20. Pro-apoptotic effect of Δ2-TGZ in "claudin-1-low" triple-negative breast cancer cells: involvement of claudin-1.
Geoffroy M; Kleinclauss A; Grandemange S; Hupont S; Boisbrun M; Flament S; Grillier-Vuissoz I; Kuntz S
Breast Cancer Res Treat; 2017 Oct; 165(3):517-527. PubMed ID: 28681173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
